Status: Recruiting
Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia
This is a prospetive,Single-Center, Single-Arm, Phase IIB Clinical Study.This study aims to evaluate the efficacy and safety of dose-attenuated IST combined with Hetrombopag in elderly patients (≥65 years) with VSAA/SAA.
Participants needed: 65
Trial details
Phase: Phase 2Age: 65+Biological sex: AllType: InterventionalSponsor: Institute of Hematology & Blood Diseases Hospital, ChinaUpdated: Jun 8, 2025Locations: 1
Eligibility criteria
Clinical diagnosis of VSAA/SAA. [+4]
Clonal cytogenetic abnormalities (excluding isolated -Y or +8). [+6]